



Cite this: *Org. Biomol. Chem.*, 2022, **20**, 1738

Synthesis of phenoxathiins using an iron-catalysed C–H thioarylation†

Amy C. Dodds and Andrew Sutherland *

Phenoxathiins are an important class of sulfur-containing heterocycle, found as the core component in numerous pharmaceutically active agents and materials. Despite this importance, there are relatively few methods for the synthesis of these heterocycles that avoid complex starting materials, harsh conditions or precious transition metals. We report a two-step synthesis of phenoxathiins from phenols using iron and copper-mediated reactions. The first step involves the accelerated *ortho*-thioarylation of phenols using *N*-(2-bromophenylthio)succinimide, catalysed by the Lewis acid, iron(III) triflimide and the Lewis base, bis(4-methoxyphenyl)sulfane. In the second step, the thioarylated products were converted to a series of phenoxathiins using a copper-mediated, Ullmann-type, C–O bond forming cyclisation reaction. The synthetic utility of this two-step approach for the preparation of biologically relevant phenoxathiins was demonstrated using natural product-based phenols.

Received 5th January 2022,
Accepted 7th February 2022

DOI: 10.1039/d2ob00022a

rscl.li/obc

Introduction

Sulfur-containing heterocycles are an important compound class,¹ found as key structural components in a wide variety of pharmaceuticals and materials.² In particular, tricyclic systems such as phenoxathiins have attracted attention due to possessing optical properties and biological activities (Scheme 1a). For example, boronic ester analogues have been developed as room-temperature phosphorescent materials,^{3,4} while 2-substituted phenoxathiins have been shown to act as inhibitors of thrombin⁵ and monoamine oxidase A,⁶ and as antifungal agents.⁷ The *S*-oxides of phenoxathiins have also been used for the C–H functionalisation of arenes.⁸

Despite the interest in phenoxathiin applications, there are relatively few methods for the synthesis of this heterocycle. Traditional methods utilised an aluminium-mediated sulfur insertion reaction of diaryl ethers under harsh conditions (Scheme 1b).⁹ More recently, several groups reported a two-step approach involving transition metal-mediated thioarylation reactions of phenols as the key step.¹⁰ Takaki and co-workers used stoichiometric amounts of iron trichloride and diaryl disulfides as the thioarylating agent (Scheme 1c).^{10a} Palladium catalysed thioarylation using an *N*-(arylthio)succinimide and trifluoroacetic acid as the solvent has also been utilised.^{10b} Other strategies to access phenoxathiins include a base-mediated coupling and cyclisation of 2-sulfanylphenol


with 1,2-dihaloarenes,¹¹ while an approach using *N*-benzyl dithiocarbamate salts as a sulfur source for copper-catalysed reaction with cyclic diaryliodoniums has also been reported.¹² Other single-step processes include the reaction of aryne intermediates with 2-hydroxyaryl 4-toluenethiosulfonates, which allowed the preparation of a wide range of phenoxathiins under mild conditions (Scheme 1d).¹³

Some of these methods allow the general synthesis of phenoxathiins bearing various substituents and functional groups. However, these methods can require harsh conditions,^{9,10b} highly functionalised starting materials,^{11–13} stoichiometric amounts of metal reagent^{10a} or the use of precious transition metal catalysts.^{10b,c} In recent years, we have reported the synthesis of various benzannulated heterocycles using earth-abundant, non-precious transition metal catalysts. This approach utilised the super Lewis acid, iron(III) triflimide for the activation of *N*-halosuccinimides and the regioselective halogenation of arenes, followed by copper-catalysed intramolecular cyclisation to form the heterocycles.¹⁴ More recently, we showed that iron(III) triflimide could also be used to activate *N*-(arylthio)succinimides for the regioselective thioarylation of arenes.¹⁵ Based on this work, we proposed that iron(III)-catalysed *ortho*-thioarylation of *para*-substituted phenols with *N*-(2-bromophenylthio)succinimide would generate an intermediate, that following a copper-mediated Ullmann-type cyclisation would allow the rapid synthesis of phenoxathiins. Herein, we now report this two-stage approach for the synthesis of phenoxathiins from phenols. As well as demonstrating the acceleration of the iron-catalysed thioarylation step using the Lewis base catalyst, bis(4-methoxyphenyl)sulfane (Scheme 1e), we also describe the straightforward application of this two-stage


School of Chemistry, The Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK. E-mail: Andrew.Sutherland@glasgow.ac.uk

† Electronic supplementary information (ESI) available: ¹H and ¹³C NMR spectra for all compounds. See DOI: 10.1039/d2ob00022a








b) Aluminium-mediated insertion of sulfur.



c) Stoichiometric iron-mediated thioarylation using diaryl disulfides.



d) Phenoxathiin synthesis via aryne intermediates.

e) **This work:** Synthesis using iron and copper-mediated reactions.

Scheme 1 a) Structures of phosphorescent and biologically active phenoxathiins. (b–e) Methods for the synthesis of phenoxathiins.

approach for the incorporation of the phenoxathiin motif into biologically active compounds.

Results and discussion

Initial development of an iron(III) triflimide-catalysed thioarylation with *N*-(2-bromophenylthio)succinimide (**2**) focused on the use of *p*-cresol (**1a**) as a suitable starting material (Table 1).¹⁶ A reaction was attempted using 10 mol% of iron(III) triflimide, which was generated *in situ* from iron(III) chloride and the readily available ionic liquid, [BMIM]NTf₂ (entry 1). The reaction showed no further conversion after 24 h and gave thioarylated product **4a**, in 38% yield. This result demonstrated that further acceleration of this reaction was required to overcome the steric constraints of *ortho*-thioarylation with *N*-(2-bromophenylthio)succinimide (**2**). During the development of our previous iron(III)-catalysed thioarylation reaction,¹⁵ kinetic studies revealed that the transformation was autocata-

Table 1 Optimisation studies for the thioarylation of *p*-cresol (**1a**)^a

Entry	FeCl ₃ (mol%)	[BMIM]NTf ₂ (mol%)	3 (mol%)	Time (h)	Yield ^b (%)
1	10	30	—	24	38
2	10	30	10	2	84
3	—	—	10	24	0
4	10	30	10	0.5	81


^a 1.2 equivalents of **2** were used. ^b Isolated yields.

lytic, in which electron-rich biaryl sulfane products acted as Lewis base catalysts, resulting in accelerated reactions. Using this information, the iron(III) triflimide-catalysed thioarylation of *p*-cresol (**1a**) with *N*-(2-bromophenylthio)succinimide (**2**) was repeated using commercially available bis(4-methoxyphenyl) sulfane (**3**) as a Lewis base catalyst (10 mol%).¹⁷ After 2 h, the reaction was found to be complete and gave **4a** in 84% yield (entry 2). To verify that the accelerated reaction was due to the combination of both iron(III) triflimide and biaryl sulfane **3**, and not just **3**, the reaction was repeated using only the Lewis base (entry 3). After 24 h, no reaction was observed, thereby confirming the dual role of both the Lewis acid and Lewis base catalysts in accelerating the reaction. Further optimisation studies investigated the actual reaction end point. Inspection of the reaction mixture using ¹H NMR spectroscopy at various time points, revealed that the reaction was complete after only 0.5 h, resulting in the isolation of **4a** in 81% yield.


The scope of the combined Lewis acid and Lewis base-catalysed *ortho*-thioarylation with a range of phenols was then explored (Scheme 2). For most substrates, the reactions were found to be fast and efficient, and gave biaryl sulfanes in good to high yields. As expected, highly activated compounds (**1b** and **1d**) were thioarylated at lower temperatures, while higher temperatures and longer reaction times (**1g**) were required for phenols bearing electron-withdrawing substituents. The use of this transformation for bi-directional thioarylation was investigated using hydroquinone (**1j**) as a starting material. This gave bis-thioarylated product **4j** in 79% yield, after a 1 h reaction time. A larger scale reaction was also investigated using 2-naphthol (**1f**). On a 5 mmol scale, the reaction proceeded as normal, providing gram quantities (1.6 g) of **4f** in similar yields to the small-scale reaction (95%).

Following the effective synthesis of a range of 2-bromobenzene phenol sulfanes **4**, these were converted to the corresponding phenoxathiins **5** using a stoichiometric amount of copper(I) thiophene-2-carboxylate under standard conditions for Ullmann-type cyclisation (Scheme 3).^{10a,b} Irrespective of the electronics or steric bulk of the substituents, all cyclisations proceeded efficiently, allowing the synthesis of various





Scheme 2 Reaction scope of phenols **1**. Isolated yields. ^a Reaction was done at 40°C . ^b Reaction was done at rt. ^c Reaction was done at 85°C . ^d 2.2 equivalents of **2** were used.




Scheme 3 Synthesis of phenoxathiins **5**. Isolated yields. ^a 2 equivalents of CuTc were used.

phenoxathiins **5** in high yields.¹⁸ This reaction also allowed the clean, double-cyclisation of **4j** and access to 5,12-dioxo-7,14-dithiapentacene (**5j**) in 82% yield. A one-pot process that combined the thioarylation and cyclisation steps was also

investigated. However, despite testing a range of solvents, the two processes were found to be incompatible due to solubility issues of the starting materials and reagents.


Having developed an efficient two-step synthesis of phenoxathiins using a commercially available Lewis base and earth abundant transition metals, the synthetic utility of this approach for incorporating this heterocyclic motif within biologically active compounds was investigated. Initially, this strategy was used for the synthesis of novel, phenoxathiin-derived α -amino acids (Scheme 4). Application of the Lewis acid and Lewis base catalysed thioarylation of commercially available tyrosine derivative **6** gave biaryl sulfane **7** in 80% yield. It should be noted that an attempt of this transformation using only iron(III) triflimide showed no reaction after 24 h. Cyclisation using copper(I) thiophene-2-carboxylate gave phenoxathiin **8** in 93% yield. Ester hydrolysis, followed by acid-mediated removal of the Cbz-protecting group gave parent α -amino acid **9** in 58% overall yield from tyrosine **6**. Diversification of the heterocyclic motif was achieved by oxidation to sulfone **10**. Treatment of **8** with hydrogen peroxide in the presence of glacial acetic acid gave sulfone **10** in 95% yield. A similar deprotection strategy gave phenoxathiin-dioxide **11** in 55% yield over the five steps.

A further demonstration of the two-step synthesis of phenoxathiins was applied to the estrogen steroid hormone, estradiol (Scheme 5). While all previous thioarylation reactions gave a single product, application of the optimised method with 17- β -estradiol-17-acetate (**12**)¹⁹ gave two products *via* reaction at the 2- or 4-*ortho* positions. Analysis of the crude reaction mixture by ¹H NMR spectroscopy showed a 6 : 1 ratio of compounds. The major product, 2-regioisomer **13** was readily separated by flash column chromatography and isolated in 73% yield. Copper(I)-mediated Ullmann-type cyclisation, followed



Scheme 4 Synthesis of phenoxathiin-derived amino acids.





Scheme 5 Synthesis of phenoxathiin-derived steroid 15.

by removal of the acetate protecting group under basic conditions gave steroid-containing phenoxathiin 15 in 52% yield over the three steps.

Based on the results from this study and the control experiments presented in Table 1, a mechanism involving both catalysts has been proposed (Scheme 6). Following formation of iron(III) triflimide from iron(III) chloride and [BMIM]NTf₂, the strongly Lewis acidic iron(III) cation activates *N*-(2-bromophenylthio)succinimide (2).^{20,21} While this intermediate can undergo slow thioarylation with the phenol, reaction instead with bis(4-methoxyphenyl)sulfane (3) forms a cationic disulfide intermediate. This charged species reacts significantly more quickly with the phenols, forming the *ortho*-thioarylated products and regenerating the Lewis base catalyst. Evidence of the cationic disulfide or a similarly reactive intermediate was observed from kinetic studies during our previous work of iron(III)-catalysed thioarylation reactions.¹⁵ These studies showed that in the absence of a Lewis base, the transformations were autocatalytic with an induction period, requiring the formation of a more reactive intermediate before rate acceleration. Addition of a Lewis base biaryl sulfide showed no induction period, confirming the role of an activated sulfide inter-


mediate in the rate acceleration. Gustafson and co-workers have also proposed cationic disulfide intermediates during their Lewis base and Brønsted acid catalysed thioarylation processes.¹⁷

Conclusions

In summary, a fast and efficient method for the *ortho*-thioarylation of phenols with *N*-(2-bromophenylthio)succinimide (2) involving the combined catalysis of the Lewis acid, iron(III) triflimide and the Lewis base, bis(4-methoxyphenyl)sulfane (3) has been developed. The transformation was found to be compatible with a wide-range of substituents and in combination with a copper(I)-mediated Ullmann-type intramolecular cyclisation allowed access to a variety of phenoxathiins. The application of this two-step approach was extended for the synthesis of more complex phenoxathiins using natural product-based phenols. The use of both tyrosine and estradiol derivatives allowed efficient access to the corresponding phenoxathiins. Overall, this work provides a new approach for the synthesis of important heterocycles using a commercially available Lewis base and earth abundant transition metals. Work is currently underway to find new applications of this general strategy.

Experimental

All reagents and starting materials, including *N*-(benzyloxycarbonyl)-L-tyrosine methyl ester (6) and bis(4-methoxyphenyl)sulfane (3) were obtained from commercial sources and used as received. *N*-(2-Bromophenylthio)succinimide (2)²² and 17-β-estradiol-17-acetate (12)¹⁹ were prepared as previously described in the literature. Reactions were performed open to air unless otherwise mentioned. Brine refers to a saturated aqueous solution of sodium chloride. Flash column chromatography was performed using silica gel 60 (35–70 μm). Aluminium-backed plates pre-coated with silica gel 60F₂₅₄ were used for thin layer chromatography and were visualised with a UV lamp or by staining with potassium permanganate. ¹H NMR spectra were recorded on an NMR spectrometer at



Scheme 6 Proposed catalytic pathway for Lewis acid and Lewis base catalysed thioarylation.



either 400 or 500 MHz and data are reported as follows: chemical shift in ppm relative to the undeuterated solvent as internal standard (CHCl₃, δ 7.26 ppm; CH₃OH, δ 3.31 ppm; DMSO, δ 2.50), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or overlap of non-equivalent resonances, integration). ¹³C NMR spectra were recorded on an NMR spectrometer at either 101 or 126 MHz and data are reported as follows: chemical shift in ppm relative to tetramethylsilane or the solvent as internal standard (CDCl₃, δ 77.16 ppm; CD₃OD, δ 49.00 ppm; DMSO-*d*₆, δ 39.52), multiplicity with respect to hydrogen (deduced from DEPT experiments, C, CH, CH₂ or CH₃). Infrared spectra were recorded on a FTIR spectrometer; wavenumbers are indicated in cm⁻¹. Mass spectra were recorded using electron impact or electro-spray techniques. HRMS spectra were recorded using dual-focusing magnetic analyser or quadrupole time of flight (Q-TOF) mass spectrometers. Melting points are uncorrected.

General procedure A: preparation of sulfenylated products 4

Iron(III) trichloride (10 mol%) was dissolved in [BMIM]NTf₂ (30 mol%) and left to stir for 0.5 h at room temperature before being added to a solution of *N*-(2-bromophenylthio)succinimide (2) (1.2 equiv.) in chloroform (0.6 M in arene), within a sealed vial. The arene (1.0 equiv.) and bis(4-methoxyphenyl) sulfane (3) (10 mol%) were then added and the reaction mixture was left to stir at the required temperature for 1–48 h. The reaction mixture was concentrated *in vacuo* and purified using flash column chromatography.

(2-Hydroxy-5-methylphenyl)(2'-bromophenyl)sulfane (4a)^{10a}

The reaction was performed as described in general procedure A using *p*-cresol (1a) (31 mg, 0.29 mmol). The reaction mixture was stirred at 75 °C for 0.5 h. Purification by flash column chromatography (hexane/dichloromethane, 4 : 1) gave (2-hydroxy-5-methylphenyl)(2'-bromophenyl)sulfane (4a) (69 mg, 81%) as a white solid. Mp 67–69 °C; spectroscopic data was consistent with the literature.^{10a} δ_{H} (400 MHz, CDCl₃) 2.31 (3H, s, CH₃), 6.21 (1H, s, OH), 6.60 (1H, dd, *J* 8.0, 1.5 Hz, 6'-H), 6.96–7.04 (2H, m, 3-H and 4'-H), 7.09–7.15 (1H, m, 5'-H), 7.23 (1H, dd, *J* 8.3, 2.0 Hz, 4-H), 7.33 (1H, d, *J* 2.0 Hz, 6-H), 7.53 (1H, dd, *J* 7.9, 1.3 Hz, 3'-H); δ_{C} (101 MHz, CDCl₃) 20.5 (CH₃), 114.8 (C), 115.7 (CH), 121.1 (C), 126.8 (CH), 127.0 (CH), 128.2 (CH), 131.2 (C), 133.1 (CH), 133.8 (CH), 137.3 (CH), 137.6 (C), 155.5 (C); *m/z* (ESI) 319 (MNa⁺, 100%).

(2-Hydroxy-4,5-dimethylphenyl)(2'-bromophenyl)sulfane (4b)

The reaction was performed as described in general procedure A using 3,4-dimethylphenol (1b) (36 mg, 0.29 mmol). The reaction mixture was stirred at 40 °C for 4 h. Purification by flash column chromatography (hexane/dichloromethane, 17 : 3) gave (2-hydroxy-4,5-dimethylphenyl)(2'-bromophenyl)sulfane (4b) (72 mg, 80%) as a white solid. Mp 86–88 °C; ν_{max} /cm⁻¹ (neat) 3446 (OH), 3012 (CH), 1479 (C=C), 1446, 1311, 1204, 1019, 747; δ_{H} (400 MHz, CDCl₃) 2.21 (3H, s, CH₃), 2.29 (3H, s, CH₃), 6.13 (1H, s, OH), 6.58 (1H, dd, *J* 8.0, 1.6 Hz, 6'-H), 6.91 (1H, s, 3-H), 6.96–7.01 (1H, m, 4'-H), 7.07–7.13 (1H, m, 5'-H), 7.26

(1H, s, 6-H), 7.52 (1H, dd, *J* 7.9, 1.3 Hz, 3'-H); δ_{C} (101 MHz, CDCl₃) 18.9 (CH₃), 20.2 (CH₃), 111.4 (C), 116.9 (CH), 120.8 (C), 126.6 (CH), 126.8 (CH), 128.1 (CH), 130.1 (C), 133.0 (CH), 137.5 (CH), 137.9 (C), 142.4 (C), 155.6 (C); *m/z* (ESI) 330.9763 (MNa⁺, C₁₄H₁₃⁷⁹BrNaOS requires 330.9763).

(2-Hydroxy-5-*t*-butylphenyl)(2'-bromophenyl)sulfane (4c)

The reaction was performed as described in general procedure A using *p*-*t*-butylphenol (1c) (44 mg, 0.29 mmol). The reaction mixture was stirred at 75 °C for 1 h. Purification by flash column chromatography (hexane/dichloromethane, 4 : 1) gave (2-hydroxy-5-*t*-butylphenyl)(2'-bromophenyl)sulfane (4c) (61 mg, 62%) as a colourless oil. ν_{max} /cm⁻¹ (neat) 3455 (OH), 2959 (CH), 1486 (C=C), 1446, 1181, 1018, 822, 744; δ_{H} (400 MHz, CDCl₃) 1.32 (9H, s, 3 × CH₃), 6.22 (1H, s, OH), 6.57 (1H, dd, *J* 8.0, 1.5 Hz, 6'-H), 7.01 (1H, td, *J* 8.0, 1.5 Hz, 4'-H), 7.05 (1H, d, *J* 8.6 Hz, 3-H), 7.12 (1H, td, *J* 8.0, 1.5 Hz, 5'-H), 7.47 (1H, dd, *J* 8.6, 2.5 Hz, 4-H), 7.53 (1H, d, *J* 2.5 Hz, 6-H), 7.54 (1H, dd, *J* 8.0, 1.5 Hz, 3'-H); δ_{C} (101 MHz, CDCl₃) 31.6 (3 × CH₃), 34.4 (C), 114.3 (C), 115.5 (CH), 120.9 (C), 126.5 (CH), 126.9 (CH), 128.2 (CH), 130.2 (CH), 133.1 (CH), 134.0 (CH), 137.7 (C), 144.8 (C), 155.4 (C); *m/z* (ESI) 359.0072 (MNa⁺, C₁₆H₁₇⁷⁹BrNaOS requires 359.0076).

[2-Hydroxy-4,5-(methylenedioxy)phenyl](2'-bromophenyl)sulfane (4d)

The reaction was performed as described in general procedure A using sesamol (1d) (40 mg, 0.29 mmol). The reaction mixture was stirred at room temperature for 3 h. Purification by flash column chromatography (hexane/dichloromethane, 7 : 3) gave [2-hydroxy-4,5-(methylenedioxy)phenyl](2'-bromophenyl)sulfane (4d) (72 mg, 76%) as a white solid. Mp 95–97 °C; ν_{max} /cm⁻¹ (neat) 3397 (OH), 2899 (CH), 1617 (C=C), 1468, 1272, 1181, 1113, 1034, 1016, 935, 856, 760; δ_{H} (400 MHz, CDCl₃) 5.99 (2H, s, CH₂), 6.27 (1H, s, OH), 6.60–6.68 (2H, m, 3-H and 6'-H), 6.92 (1H, s, 6-H), 7.01 (1H, td, *J* 7.8, 1.6 Hz, 4'-H), 7.11–7.16 (1H, m, 5'-H), 7.52 (1H, dd, *J* 7.8, 1.3 Hz, 3'-H); δ_{C} (101 MHz, CDCl₃) 97.9 (CH₂), 101.9 (CH), 104.5 (C), 114.7 (CH), 120.8 (C), 126.5 (CH), 127.1 (CH), 128.2 (CH), 133.1 (CH), 137.9 (C), 142.2 (C), 151.6 (C), 154.1 (C); *m/z* (ESI) 346.9348 (MNa⁺, C₁₃H₉⁷⁹BrNaO₃S requires 346.9348).

(2-Hydroxy-5-biphenyl)(2'-bromophenyl)sulfane (4e)

The reaction was performed as described in general procedure A using 4-phenylphenol (1e) (50 mg, 0.29 mmol). The reaction mixture was stirred at 75 °C for 1 h. Purification by flash column chromatography (hexane/ethyl acetate, 49 : 1) gave (2-hydroxy-5-biphenyl)(2'-bromophenyl)sulfane (4e) (79 mg, 76%) as a colourless oil. ν_{max} /cm⁻¹ (neat) 3440 (OH), 3028 (CH), 1504 (C=C), 1472 (C=C), 1285, 1174, 1018, 830, 742; δ_{H} (400 MHz, CDCl₃) 6.40 (1H, s, OH), 6.68 (1H, dd, *J* 8.0, 1.6 Hz, 6''-H), 6.99–7.05 (1H, m, 4''-H), 7.10–7.16 (1H, m, 5''-H), 7.19 (1H, d, *J* 8.5 Hz, 3-H), 7.31–7.36 (1H, m, 4'-H), 7.40–7.46 (2H, m, 3'-H and 5'-H), 7.53–7.60 (3H, m, 2'-H, 6'-H and 3''-H), 7.68 (1H, dd, *J* 8.5, 2.3 Hz, 4-H), 7.79 (1H, d, *J* 2.3 Hz, 6-H); δ_{C} (101 MHz, CDCl₃) 115.9 (C), 116.4 (CH), 121.3 (C), 126.8 (2 ×



CH), 127.0 (CH), 127.2 (CH), 127.3 (CH), 128.3 (CH), 129.0 (2 × CH), 131.7 (CH), 133.2 (CH), 135.1 (C), 135.7 (CH), 137.2 (C), 139.7 (C), 157.1 (C); m/z (ESI) 378.9761 (MNa⁺. C₁₈H₁₃⁷⁹BrNaOS requires 378.9763).

(2-Hydroxynaphthalen-1-yl)(2'-bromophenyl)sulfane (4f)^{10b}

The reaction was performed as described in general procedure A using 2-naphthol (**1f**) (0.72 g, 5.0 mmol). The reaction mixture was stirred at 75 °C for 1 h. Purification by flash column chromatography (hexane/dichloromethane, 4 : 1) gave (2-hydroxynaphthalen-1-yl)(2'-bromophenyl)sulfane (**4f**) (1.6 g, 95%) as a colourless oil. Spectroscopic data was consistent with the literature.^{10b} δ_{H} (400 MHz, CDCl₃) 6.32–6.37 (1H, m, 6'-H), 6.92–7.00 (2H, m, 4'-H and 5'-H), 7.02 (1H, s, OH), 7.36 (1H, d, J 8.9 Hz, 3-H), 7.40 (1H, ddd, J 8.1, 6.9, 1.2 Hz, 6-H), 7.51 (1H, ddd, J 8.4, 6.9, 1.3 Hz, 7-H), 7.54–7.59 (1H, m, 3'-H), 7.84 (1H, dd, J 8.1, 1.3 Hz, 5-H), 7.96 (1H, d, J 8.9 Hz, 4-H), 8.15 (1H, dd, J 8.4, 1.2 Hz, 8-H); δ_{C} (101 MHz, CDCl₃) 107.3 (C), 117.2 (CH), 121.2 (C), 124.2 (CH), 124.7 (CH), 126.5 (CH), 127.0 (CH), 128.1 (CH), 128.4 (CH), 128.8 (CH), 129.7 (C), 133.1 (CH), 133.5 (CH), 135.4 (C), 136.6 (C), 157.4 (C); m/z (ESI) 355 (MNa⁺. 100%).

3-(2'-Bromophenylthio)-4-hydroxybenzaldehyde (4g)

Iron(III) trichloride (4.7 mg, 0.029 mmol) was dissolved in [BMIM]NTf₂ (25 μ L, 0.087 mmol) and left to stir for 0.5 h at room temperature before being added to a solution of *N*-(2-bromophenylthio)succinimide (**2**) (100 mg, 0.35 mmol) in chloroform (0.5 mL). 4-Hydroxybenzaldehyde (**1g**) (36 mg, 0.29 mmol) and bis(4-methoxyphenyl)sulfane (**3**) (7.2 mg, 0.029 mmol) was then added and the reaction mixture was left to stir at 85 °C for 24 h. Further *N*-(2-bromophenylthio)succinimide (**2**) (100 mg, 0.35 mmol) was added and the reaction mixture was left to stir at 85 °C for a further 24 h. The reaction mixture was concentrated *in vacuo* and purified using flash column chromatography (hexane/dichloromethane 1 : 1) to give 3-(2'-bromophenylthio)-4-hydroxybenzaldehyde (**4g**) (49 mg, 54%) as an off-white solid. Mp 136–138 °C; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 3207 (OH), 1663 (C=O), 1593 (C=C), 1558, 1488, 1263, 1147, 1018, 745, 719; δ_{H} (400 MHz, CDCl₃) 6.64 (1H, dd, J 7.9, 1.6 Hz, 6'-H), 7.03–7.08 (2H, m, 4-OH and 4'-H), 7.12–7.16 (1H, m, 5'-H), 7.22 (1H, d, J 8.5 Hz, 5-H), 7.56 (1H, dd, J 7.9, 1.4 Hz, 3'-H), 7.97 (1H, dd, J 8.5, 2.0 Hz, 6-H), 8.08 (1H, d, J 2.0 Hz, 2-H), 9.87 (1H, s, CHO); δ_{C} (101 MHz, CDCl₃) 116.8 (CH), 117.3 (C), 121.9 (C), 127.5 (CH), 127.9 (CH), 128.4 (CH), 131.0 (C), 133.4 (CH), 134.1 (CH), 136.0 (C), 140.0 (CH), 162.6 (C), 189.9 (CH); m/z (ESI) 330.9397 (MNa⁺. C₁₃H₉⁷⁹BrNaO₂S requires 330.9399).

(2-Hydroxy-5-chlorophenyl)(2'-bromophenyl)sulfane (4h)

The reaction was performed as described in general procedure A using 4-chlorophenol (**1h**) (37 mg, 0.29 mmol). The reaction mixture was stirred at 75 °C for 2 h. Purification by flash column chromatography (hexane/dichloromethane, 4 : 1) gave (2-hydroxy-5-chlorophenyl)(2'-bromophenyl)sulfane (**4h**) (50 mg, 54%) as a white solid. Mp 77–79 °C; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat)

3391 (OH), 3050 (CH), 1464 (C=C), 1447, 1188, 1017, 817, 740; δ_{H} (400 MHz, CDCl₃) 6.36 (1H, s, OH), 6.64 (1H, dd, J 7.9, 1.5 Hz, 6'-H), 7.00–7.08 (2H, m, 3-H and 4'-H), 7.15 (1H, td, J 7.9, 1.4 Hz, 5'-H), 7.38 (1H, dd, J 8.8, 2.6 Hz, 4-H), 7.52 (1H, d, J 2.6 Hz, 6-H), 7.55 (1H, dd, J 7.9, 1.4 Hz, 3'-H); δ_{C} (101 MHz, CDCl₃) 117.1 (C), 117.2 (CH), 121.6 (C), 125.9 (C), 127.2 (CH), 127.6 (CH), 128.4 (CH), 132.9 (CH), 133.3 (CH), 136.2 (CH), 136.4 (C), 156.3 (C); m/z (ESI) 336.9059 (MNa⁺. C₁₂H₈⁷⁹Br³⁵ClNaOS requires 336.9060).

(2-Hydroxy-5-fluorophenyl)(2'-bromophenyl)sulfane (4i)

The reaction was performed as described in general procedure A using 4-fluorophenol (**1i**) (33 mg, 0.29 mmol). The reaction mixture was stirred at 75 °C for 3 h. Purification by flash column chromatography (hexane/dichloromethane, 9 : 1) gave (2-hydroxy-5-fluorophenyl)(2'-bromophenyl)sulfane (**4i**) (30 mg, 34%) as a colourless oil. $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 3437 (OH), 3061 (CH), 1478 (C=C), 1445, 1194, 1017, 818, 770, 743; δ_{H} (400 MHz, CDCl₃) 6.20 (1H, s, OH), 6.66 (1H, dd, J 8.0, 1.5 Hz, 6'-H), 7.01–7.08 (2H, m, 3-H and 4'-H), 7.11–7.17 (2H, m, 6-H and 5'-H), 7.22–7.27 (1H, m, 4-H), 7.55 (1H, dd, J 7.9, 1.4 Hz, 3'-H); δ_{C} (101 MHz, CDCl₃) 116.3 (d, $^3J_{\text{CF}}$ 8.3 Hz, C), 116.8 (d, $^3J_{\text{CF}}$ 7.9 Hz, CH), 119.9 (d, $^2J_{\text{CF}}$ 23.0 Hz, CH), 121.7 (C), 122.7 (d, $^2J_{\text{CF}}$ 23.1 Hz, CH), 127.3 (CH), 127.6 (CH), 128.3 (CH), 133.3 (CH), 136.5 (C), 154.0 (d, $^4J_{\text{CF}}$ 2.4 Hz, C), 156.7 (d, $^1J_{\text{CF}}$ 242.1 Hz, C); m/z (ESI) 296.9392 ([M – H][−]. C₁₂H₇⁷⁹BrFOS requires 296.9391).

1,4-Bis-[(2'-bromophenyl)sulfane]-2,5-dihydroxybenzene (4j)

Iron(III) trichloride (5.2 mg, 0.032 mmol) was dissolved in [BMIM]NTf₂ (28 μ L, 0.095 mmol) and left to stir for 0.5 h at room temperature before being added to a solution of *N*-(2-bromophenylthio)succinimide (**2**) (200 mg, 0.70 mmol) in chloroform (0.6 mL). Hydroquinone (**1j**) (35 mg, 0.32 mmol) and bis(4-methoxyphenyl)sulfane (**3**) (7.8 mg, 0.032 mmol) was then added and the reaction mixture was left to stir at 75 °C for 1 h. The reaction mixture was concentrated *in vacuo* and purified using flash column chromatography (hexane/dichloromethane 3 : 2) to give 1,4-bis-[(2'-bromophenyl)sulfane]-2,5-dihydroxybenzene (**4j**) (121 mg, 79%) as a white solid. Mp 189–190 °C; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 3414 (OH), 3056 (CH), 1458 (C=C), 1443, 1302, 1189, 1018, 798, 739; δ_{H} (400 MHz, CDCl₃) 5.98 (2H, s, 2 × OH), 6.81 (2H, dd, J 7.8, 1.5 Hz, 2 × 6'-H), 7.07 (2H, td, J 7.8, 1.5 Hz, 2 × 4'-H), 7.19 (2H, td, J 7.8, 1.5 Hz, 2 × 5'-H), 7.24 (2H, s, 3-H and 6-H), 7.57 (2H, dd, J 7.8, 1.5 Hz, 2 × 3'-H); δ_{C} (101 MHz, CDCl₃) 120.6 (2 × C), 122.3 (2 × C), 122.5 (2 × CH), 127.9 (2 × CH), 128.1 (2 × CH), 128.4 (2 × CH), 133.4 (2 × CH), 136.1 (2 × C), 151.1 (2 × C); m/z (ESI) 482.8698 (MH⁺. C₁₈H₁₃⁷⁹Br₂O₂S₂ requires 482.8718).

General procedure B: preparation of phenoxathiins 5

To a solution of biaryl sulfide (1.0 equiv.) in *N,N*-dimethylacetamide (0.03 M in arene) was added copper(I) thiophene-2-carboxylate (1.0 equiv.). The reaction mixture was stirred at 100 °C for 18 h. The reaction mixture was extracted with ethyl acetate (30 mL) and washed with 5% aqueous lithium chloride



(2 × 30 mL), dried over MgSO₄, filtered and concentrated *in vacuo*. The resulting material was purified by flash column chromatography.

2-Methylphenoxathiin (5a)^{10a}

The reaction was performed as described in general procedure B using (2-hydroxy-5-methylphenyl)(2'-bromophenyl)sulfane (4a) (60 mg, 0.46 mmol). Purification by flash column chromatography (hexane) gave 2-methylphenoxathiin (5a) (38 mg, 86%) as a colourless oil. Spectroscopic data was consistent with the literature.^{10a} δ_{H} (500 MHz, CDCl₃) 2.26 (3H, s, CH₃), 6.87–6.93 (3H, m, 1-H, 3-H and 4-H), 6.97–7.02 (2H, m, 6-H and 8-H), 7.07–7.14 (2H, m, 7-H and 9-H); δ_{C} (126 MHz, CDCl₃) 20.7 (CH₃), 117.5 (CH), 117.9 (CH), 119.7 (C), 120.3 (C), 124.4 (CH), 126.9 (CH), 127.2 (CH), 127.7 (CH), 128.4 (CH), 134.3 (C), 150.0 (C), 152.5 (C); m/z (ESI) 214 (M⁺, 100%).

2,3-Dimethylphenoxathiin (5b)

The reaction was performed as described in general procedure B using (2-hydroxy-4,5-dimethylphenyl)(2'-bromophenyl)sulfane (4b) (50 mg, 0.16 mmol). Purification by flash column chromatography (hexane) gave 2,3-dimethylphenoxathiin (5b) (30 mg, 81%) as a white solid. Mp 117–119 °C; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 2984 (CH), 1449 (C=C), 1441, 1218, 1023, 874, 756; δ_{H} (400 MHz, CDCl₃) 2.17 (3H, s, CH₃), 2.20 (3H, s, CH₃), 6.81 (1H, s, 4-H), 6.85 (1H, s, 1-H), 6.95–7.01 (2H, m, 6-H and 8-H), 7.06–7.13 (2H, m, 7-H and 9-H); δ_{C} (101 MHz, CDCl₃) 19.0 (CH₃), 19.6 (CH₃), 116.2 (C), 117.8 (CH), 118.9 (CH), 120.6 (C), 124.3 (CH), 126.9 (CH), 127.4 (CH), 127.6 (CH), 132.9 (C), 136.4 (C), 150.1 (C), 152.5 (C); m/z (ESI) 251.0502 (MNa⁺, C₁₄H₁₂NaOS requires 251.0501).

2-*t*-Butylphenoxathiin (5c)

The reaction was performed as described in general procedure B using (2-hydroxy-5-*t*-butylphenyl)(2'-bromophenyl)sulfane (4c) (55 mg, 0.16 mmol). Purification by flash column chromatography (hexane) gave 2-*t*-butylphenoxathiin (5c) (35 mg, 83%) as a colourless oil. $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 2960 (CH), 1462 (C=C), 1442, 1262, 1227, 853, 750; δ_{H} (400 MHz, CDCl₃) 1.29 (9H, s, 3 × CH₃), 6.95 (1H, d, *J* 8.4 Hz, 4-H), 6.97–7.02 (2H, m, 6-H and 8-H), 7.09–7.16 (4H, m, 1-H, 3-H, 7-H and 9-H); δ_{C} (101 MHz, CDCl₃) 31.5 (3 × CH₃), 34.5 (C), 117.3 (CH), 117.9 (CH), 119.4 (C), 120.4 (C), 123.8 (CH), 124.5 (CH), 124.9 (CH), 126.9 (CH), 127.7 (CH), 147.8 (C), 150.0 (C), 152.5 (C); m/z (ESI) 279.0815 (MNa⁺, C₁₆H₁₆NaOS requires 279.0814).

2,3-(Methylenedioxy)phenoxathiin (5d)

The reaction was performed as described in general procedure B using [2-hydroxy-4,5-(methylenedioxy)phenyl](2'-bromophenyl)sulfane (4d) (54 mg, 0.17 mmol). Purification by flash column chromatography (hexane/dichloromethane 4 : 1) gave 2,3-(methylenedioxy)phenoxathiin (5d) (38 mg, 93%) as a colourless oil. $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 2888 (CH), 1459 (C=C), 1219, 1118, 1032, 933, 850, 746; δ_{H} (400 MHz, CDCl₃) 5.94 (2H, s, CH₂), 6.57 (1H, s, 4-H), 6.62 (1H, s, 1-H), 6.98–7.04 (2H, m, 6-H and 8-H), 7.10–7.16 (2H, m, 7-H and 9-H); δ_{C} (101 MHz,

CDCl₃) 100.6 (CH), 101.8 (CH₂), 106.2 (CH), 111.4 (C), 117.8 (CH), 121.0 (C), 124.7 (CH), 126.9 (CH), 127.9 (CH), 144.6 (C), 147.4 (C), 147.5 (C), 152.9 (C); m/z (ESI) 267.0087 (MNa⁺, C₁₃H₈NaO₃S requires 267.0086).

2-Phenylphenoxathiin (5e)

The reaction was performed as described in general procedure B using (2-hydroxy-5-biphenyl)(2'-bromophenyl)sulfane (4e) (65 mg, 0.18 mmol). Purification by flash column chromatography (hexane) gave 2-phenylphenoxathiin (5e) (42 mg, 84%) as a white solid. Mp 85–86 °C; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 3056 (CH), 1456 (C=C), 1439 (C=C), 1262, 1210, 1077, 938, 745; δ_{H} (400 MHz, CDCl₃) 6.98–7.05 (2H, m, 6-H and 8-H), 7.07 (1H, d, *J* 8.3 Hz, 4-H), 7.10–7.18 (2H, m, 7-H and 9-H), 7.29–7.39 (3H, m, 1-H, 3-H and 4'-H), 7.40–7.47 (2H, m, 3'-H and 5'-H), 7.50–7.56 (2H, m, 2'-H and 6'-H); δ_{C} (101 MHz, CDCl₃) 117.9 (CH), 118.1 (CH), 119.9 (C), 120.5 (C), 124.7 (CH), 125.4 (CH), 126.6 (CH), 126.9 (2 × CH), 127.0 (CH), 127.5 (CH), 127.9 (CH), 129.0 (2 × CH), 138.0 (C), 139.9 (C), 151.6 (C), 152.2 (C); m/z (ESI) 299.0501 (MNa⁺, C₁₈H₁₂NaOS requires 299.0501).

Benzo[*a*]phenoxathiin (5f)²³

The reaction was performed as described in general procedure B using (2-hydroxynaphthalen-1-yl)(2'-bromophenyl)sulfane (4f) (80 mg, 0.24 mmol). Purification by flash column chromatography (hexane) gave 2-methylphenoxathiin (5f) (50 mg, 83%) as a white solid. Mp 63–64 °C (lit.²³ 63 °C); δ_{H} (400 MHz, CDCl₃) 7.02–7.08 (2H, m, 11-H and 13-H), 7.13–7.24 (3H, m, 1-H, 10-H and 12-H), 7.44 (1H, ddd, *J* 8.1, 6.9, 1.0 Hz, 4-H), 7.55 (1H, ddd, *J* 8.4, 6.9, 1.3 Hz, 5-H), 7.65 (1H, d, *J* 8.8 Hz, 2-H), 7.79 (1H, dd, *J* 8.1, 1.3 Hz, 3-H), 7.92 (1H, dd, *J* 8.4, 1.0 Hz, 6-H); δ_{C} (101 MHz, CDCl₃) 113.6 (C), 117.8 (CH), 118.5 (CH), 119.7 (C), 123.1 (CH), 124.8 (CH), 125.1 (CH), 127.0 (CH), 127.2 (CH), 127.8 (CH), 128.1 (CH), 128.5 (CH), 130.3 (C), 131.1 (C), 149.8 (C), 152.5 (C); m/z (ESI) 273 (MNa⁺, 100%).

2-Formylphenoxathiin (5g)

The reaction was performed as described in general procedure B using 3-(2'-bromophenylthio)-4-hydroxybenzaldehyde (4g) (53 mg, 0.17 mmol). Purification by flash column chromatography (hexane/dichloromethane 7 : 3) gave 2-formylphenoxathiin (5g) (36 mg, 92%) as a yellow solid. Mp 82–83 °C; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 2727 (CH), 1683 (C=O), 1592 (C=C), 1466, 1238, 1198, 1080, 810, 752; δ_{H} (400 MHz, CDCl₃) 6.97–7.08 (4H, m, 4-H, 6-H, 8-H and 9-H), 7.14 (1H, ddd, *J* 8.0, 6.9, 2.1 Hz, 7-H), 7.59 (1H, d, *J* 2.0 Hz, 1-H), 7.62 (1H, dd, *J* 8.3, 2.0 Hz, 3-H), 9.84 (1H, s, CHO); δ_{C} (101 MHz, CDCl₃) 118.0 (CH), 118.3 (CH), 118.6 (C), 121.4 (C), 125.4 (CH), 126.9 (CH), 128.1 (CH), 128.2 (CH), 130.2 (CH), 133.3 (C), 150.9 (C), 156.6 (C), 190.1 (CH); m/z (ESI) 251.0136 (MNa⁺, C₁₃H₈NaO₂S requires 251.0137).

2-Chlorophenoxathiin (5h)

The reaction was performed as described in general procedure B using (2-hydroxy-5-chlorophenyl)(2'-bromophenyl)sulfane (4h) (40 mg, 0.13 mmol). Purification by flash column chrom-



atography (hexane) gave 2-chlorophenoxathiin (**5h**) (25 mg, 83%) as a white solid. Mp 88–90 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3059 (CH), 1462 (C=C), 1439, 1377, 1285, 1261, 1099, 799, 737; δ_{H} (400 MHz, CDCl_3) 6.89–6.94 (1H, m, 6-H), 6.96–7.10 (5H, m, 1-H, 3-H, 4-H, 8-H and 9-H), 7.14 (1H, ddd, J 7.9, 7.4, 1.8 Hz, 7-H); δ_{C} (101 MHz, CDCl_3) 118.0 (CH), 118.8 (CH), 119.2 (C), 122.2 (C), 124.9 (CH), 126.4 (CH), 126.9 (CH), 127.7 (CH), 128.1 (CH), 129.5 (C), 150.9 (C), 152.0 (C); m/z (ESI) 234.9958 (MH^+ . $\text{C}_{12}\text{H}_8^{35}\text{CLOS}$ requires 234.9979).

2-Fluorophenoxathiin (**5i**)

The reaction was performed as described in general procedure B using (2-hydroxy-5-fluorophenyl)(2'-bromophenyl)sulfane (**4i**) (45 mg, 0.15 mmol). Purification by flash column chromatography (hexane) gave 2-fluorophenoxathiin (**5i**) (30 mg, 91%) as a white solid. Mp 58–60 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3062 (CH), 1458 (C=C), 1442, 1245, 1183, 853, 753; δ_{H} (400 MHz, CDCl_3) 6.78–6.85 (2H, m, 1-H and 3-H), 6.95 (1H, ddd, J 8.5, 4.8, 0.7 Hz, 4-H), 6.99–7.04 (2H, m, 6-H and 8-H), 7.09 (1H, dd, J 7.7, 1.7 Hz, 9-H), 7.12–7.17 (1H, m, 7-H); δ_{C} (101 MHz, CDCl_3) 113.5 (d, $^2J_{\text{CF}}$ 26.0 Hz, CH), 114.3 (d, $^2J_{\text{CF}}$ 23.3 Hz, CH), 118.0 (CH), 118.7 (d, $^3J_{\text{CF}}$ 8.6 Hz, CH), 119.3 (C), 122.1 (d, $^3J_{\text{CF}}$ 8.9 Hz, C), 124.8 (CH), 126.9 (CH), 128.1 (CH), 148.4 (d, $^4J_{\text{CF}}$ 2.7 Hz, C), 152.3 (C), 159.3 (d, $^1J_{\text{CF}}$ 243.9 Hz, C); m/z (ESI) 236.0529 (MNH_4^+ . $\text{C}_{12}\text{H}_{11}\text{FNOS}$ requires 236.0540).

5,12-Dioxa-7,14-dithiapentacene (**5j**)

To a solution of 1,4-bis-[(2'-bromophenyl)sulfane]-2,5-dihydroxybenzene (**4j**) (90 mg, 0.19 mmol) in *N,N*-dimethylacetamide (6.4 mL) was added copper(i) thiophene-2-carboxylate (71 mg, 0.37 mmol). The reaction mixture was stirred at 100 °C for 18 h. The reaction mixture was extracted with ethyl acetate (30 mL) and washed with 5% aqueous lithium chloride (2 × 30 mL), dried over MgSO_4 , filtered and concentrated *in vacuo*. Purification by flash column chromatography (hexane/dichloromethane 9 : 1) gave 5,12-dioxa-7,14-dithiapentacene (**5j**) (49 mg, 82%) as a white solid. Mp 216–218 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3070 (CH), 1450 (C=C), 1439, 1370, 1261, 1205, 1169, 874, 747; δ_{H} (400 MHz, CDCl_3) 6.77 (2H, s, 6-H and 13-H), 6.95–7.03 (4H, m, 2 × 2-H and 2 × 4-H), 7.07–7.15 (4H, m, 2 × 1-H and 2 × 3-H); δ_{C} (101 MHz, CDCl_3) 115.5 (2 × CH), 118.0 (2 × CH), 119.3 (2 × C), 119.5 (2 × C), 124.8 (2 × CH), 126.9 (2 × CH), 128.1 (2 × CH), 148.7 (2 × C), 152.1 (2 × C); m/z (ESI) 340.0465 ($[\text{MNH}_4]^+$. $\text{C}_{18}\text{H}_{14}\text{NO}_2\text{S}_2$ requires 340.0460).

N-(Benzyloxycarbonyl)-[3'-(2''-bromophenylthio)]-L-tyrosine methyl ester (**7**)

The reaction was performed as described in general procedure A using *N*-(benzyloxycarbonyl)-L-tyrosine methyl ester (**6**) (192 mg, 0.582 mmol). The reaction mixture was stirred at 75 °C for 20 h. Purification by flash column chromatography (dichloromethane) gave *N*-(benzyloxycarbonyl)-[3'-(2''-bromophenylthio)]-L-tyrosine methyl ester (**7**) (240 mg, 80%) as a colourless oil. $\nu_{\max}/\text{cm}^{-1}$ (neat) 3379 (OH), 3318 (NH), 2948 (CH), 1705 (CO), 1507 (C=C), 1446, 1216, 1019, 757; $[\alpha]_{\text{D}}^{25} +42.7$ (c 0.1, CHCl_3); δ_{H} (400 MHz, CDCl_3) 3.01 (1H, dd, J 14.0, 5.8 Hz,

3-*HH*), 3.11 (1H, dd, J 14.0, 5.5 Hz, 3-*HH*), 3.67 (3H, s, CO_2CH_3), 4.63 (1H, ddd, J 8.0, 5.8, 5.5 Hz, 2-H), 5.07 (1H, d, J 12.2 Hz, Ph*CHH*), 5.10 (1H, d, J 12.2 Hz, Ph*CHH*), 5.29 (1H, d, J 8.0 Hz, NH), 6.36 (1H, s, OH), 6.53 (1H, dd, J 8.0, 1.5 Hz, 6''-H), 6.95–7.03 (2H, m, 5'-H and 4''-H), 7.05–7.12 (1H, m, 5''-H), 7.15 (1H, dd, J 8.4, 2.2 Hz, 6'-H), 7.28–7.39 (6H, m, 2'-H and Ph), 7.52 (1H, dd, J 7.9, 1.3 Hz, 3''-H); δ_{C} (101 MHz, CDCl_3) 37.4 (CH_2), 52.6 (CH_3), 55.0 (CH), 67.2 (CH_2), 115.4 (C), 116.2 (CH), 121.1 (C), 126.8 (CH), 127.1 (CH), 128.2 (2 × CH), 128.3 (CH), 128.4 (CH), 128.7 (2 × CH), 129.2 (C), 133.1 (CH), 133.9 (CH), 136.3 (C), 137.3 (C), 137.9 (CH) 155.6 (C), 156.8 (C), 171.8 (C); m/z (ESI) 538.0288 (MNa^+ . $\text{C}_{24}\text{H}_{22}^{79}\text{BrNNaO}_5\text{S}$ requires 538.0294).

Methyl (2*S*)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-2'-yl)propanoate (**8**)

The reaction was performed as described in general procedure B using *N*-(benzyloxycarbonyl)-[3'-(2''-bromophenylthio)]-L-tyrosine methyl ester (**7**) (100 mg, 0.194 mmol). Purification by flash column chromatography (dichloromethane) gave methyl (2*S*)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-2'-yl)propanoate (**8**) (78.0 mg, 93%) as a colourless oil. $\nu_{\max}/\text{cm}^{-1}$ (neat) 3342 (NH), 2950 (CH), 1699 (CO), 1511 (C=C), 1464, 1442, 1230, 1206, 1056, 747; $[\alpha]_{\text{D}}^{25} +48.7$ (c 0.1, CHCl_3); δ_{H} (400 MHz, CDCl_3) 2.98 (1H, dd, J 14.0, 6.0 Hz, 3-*HH*), 3.06 (1H, dd, J 14.0, 5.6 Hz, 3-*HH*), 3.73 (3H, s, CO_2CH_3), 4.62 (1H, ddd, J 8.0, 6.0, 5.6 Hz, 2-H), 5.08 (1H, d, J 12.2 Hz, Ph*CHH*), 5.13 (1H, d, J 12.2 Hz, Ph*CHH*), 5.23 (1H, d, J 8.0 Hz, NH), 6.81–6.85 (2H, m, 1'-H and 4'-H), 6.87–6.91 (1H, m, 3'-H), 6.97–7.02 (2H, m, 6'-H and 8'-H), 7.08 (1H, dd, J 7.7, 1.5 Hz, 9'-H), 7.10–7.14 (1H, m, 7'-H), 7.29–7.38 (5H, m, Ph); δ_{C} (101 MHz, CDCl_3) 37.5 (CH_2), 52.6 (CH_3), 54.9 (CH), 67.2 (CH_2), 117.9 (CH), 118.0 (CH), 119.9 (C), 120.5 (C), 124.7 (CH), 126.9 (CH), 127.5 (CH), 127.9 (CH), 128.2 (2 × CH), 128.4 (CH), 128.7 (CH), 128.7 (2 × CH), 132.3 (C), 136.3 (C), 151.4 (C), 152.2 (C), 155.7 (C) 171.9 (C); m/z (ESI) 458.1031 (MNa^+ . $\text{C}_{24}\text{H}_{21}\text{NNaO}_5\text{S}$ requires 458.1033).

(2*S*)-2-[(Benzyloxycarbonyl)amino]-3-(phenoxathiin-2'-yl)propanoic acid

To a stirred solution of methyl (2*S*)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-2'-yl)propanoate (**8**) (130 mg, 0.299 mmol) in methanol (6 mL), 1,4-dioxane (3 mL) and water (3 mL) was added cesium carbonate (126 mg, 0.388 mmol). The resulting reaction mixture was left to stir at room temperature for 20 h. The reaction mixture was concentrated *in vacuo*, diluted with water (20 mL) and acidified to pH 1 with 1 M aqueous hydrochloric acid. The aqueous layer was extracted with dichloromethane (3 × 20 mL). The combined organic layers were dried over MgSO_4 , filtered and concentrated under reduced pressure to give (2*S*)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-2'-yl)propanoic acid as a colourless oil (103 mg, 82%). $\nu_{\max}/\text{cm}^{-1}$ (neat) 3306 (OH), 2920 (CH), 1697 (CO), 1462 (C=C), 1265, 1231, 1053, 748; $[\alpha]_{\text{D}}^{20} +7.1$ (c 0.1, MeOH); δ_{H} (400 MHz, CD_3OD) 2.84 (1H, dd, J 14.0, 9.4 Hz, 3-*HH*), 3.13 (1H, dd, J 14.0, 4.8 Hz, 3-*HH*), 4.39 (1H, dd, J 9.4, 4.8 Hz, 2-H), 4.98 (1H, d, J 12.5 Hz, Ph*CHH*), 5.06 (1H, d, J 12.5 Hz, Ph*CHH*), 6.88 (1H, d, J 8.2 Hz, 6'-H), 6.96–7.06 (4H, m, 1'-



H, 4'-H, 8'-H and 9'-H), 7.10 (1H, dd, J 7.7, 1.5 Hz, 3'-H), 7.12–7.31 (5H, m, 7'-H and Ph); δ_C (101 MHz, CD₃OD) 37.8 (CH₂), 56.7 (CH), 67.5 (CH₂), 118.5 (CH), 118.7 (CH), 121.1 (C), 121.3 (C), 125.7 (CH), 127.8 (CH), 128.5 (CH), 128.6 (2 × CH), 128.9 (CH), 129.0 (CH), 129.4 (2 × CH), 129.9 (CH), 135.4 (C), 138.2 (C), 152.3 (C), 153.5 (C), 158.4 (C), 175.0 (C); m/z (ESI) 422.1060 (MH⁺. C₂₃H₂₀NO₅S requires 422.1057).

(2S)-2-Amino-3-(phenoxathiin-2'-yl)propanoic acid hydrochloride (9)

A solution of (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-2'-yl)propanoic acid (75 mg, 0.16 mmol) in 6 M aqueous hydrochloric acid (7.5 mL) and 1,4-dioxane (1.5 mL) was heated under reflux for 4 h. After cooling to room temperature, the reaction mixture was concentrated *in vacuo* and the resulting residue recrystallised from methanol and diethyl ether to afford (2S)-2-amino-3-(phenoxathiin-2'-yl)propanoic acid hydrochloride (9) as a white solid (49 mg, 95%). Mp 234–236 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3387 (NH), 2889 (OH), 1728 (CO), 1470 (C=C), 1439, 1265, 1200, 1123, 741; $[\alpha]_D^{21}$ -3.1 (c 0.1, MeOH); δ_H (400 MHz, CD₃OD) 3.09 (1H, dd, J 14.6, 7.7 Hz, 3-HH), 3.25 (1H, dd, J 14.6, 5.5 Hz, 3-HH), 4.22 (1H, dd, J 7.7, 5.5 Hz, 2-H), 6.99–7.20 (7H, m, 1'-H, 3'-H, 4'-H, 6'-H, 7'-H, 8'-H and 9'-H); δ_C (101 MHz, CD₃OD) 36.4 (CH₂), 55.0 (CH), 118.7 (CH), 119.2 (CH), 120.9 (C), 122.2 (C), 126.0 (CH), 127.9 (CH), 128.8 (CH), 129.2 (CH), 130.1 (CH), 132.3 (C), 153.2 (C), 153.4 (C), 171.2 (C); m/z (ESI) 288.0690 (MH⁺. C₁₅H₁₄NO₃S requires 288.0689).

Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoate (10)

Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-2'-yl)propanoate (8) (60.0 mg, 0.138 mmol) was dissolved in dichloromethane (1.30 mL) with stirring under argon. Glacial acetic acid (217 μL , 3.79 mmol) was then added to the solution followed by 30% H₂O₂ (78.0 μL). The reaction mixture was stirred at 50 °C for 20 h. The reaction mixture was cooled to room temperature and diluted with dichloromethane (20 mL). The organic layer was washed with water (20 mL) and the aqueous layer was further extracted with dichloromethane (2 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by flash chromatography (dichloromethane/methanol 199:1) gave methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoate (10) (62.0 mg, 75%) as a white solid. Mp 122–124 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3348 (NH), 2954 (CH), 1714 (CO), 1520 (C=C), 1469, 1273, 1152, 1063, 757; $[\alpha]_D^{25}$ +65.9 (c 0.1, CHCl₃); δ_H (400 MHz, CDCl₃) 3.15 (1H, dd, J 14.0, 6.2 Hz, 3-HH), 3.26 (1H, dd, J 14.0, 5.4 Hz, 3-HH), 3.75 (3H, s, CO₂CH₃), 4.67 (1H, ddd, J 7.6, 6.2, 5.4 Hz, 2-H), 5.10 (2H, s, PhCH₂), 5.42 (1H, d, J 7.6 Hz, NH), 7.26–7.43 (9H, m, 3'-H, 4'-H, 6'-H, 8'-H and Ph), 7.61–7.67 (1H, m, 7'-H), 7.79 (1H, d, J 1.9 Hz, 1'-H), 8.04 (1H, dd, J 7.9, 1.2 Hz, 9'-H); δ_C (101 MHz, CDCl₃) 37.7 (CH₂), 52.8 (CH₃), 54.8 (CH), 67.2 (CH₂), 119.0 (CH), 119.2 (CH), 123.5 (CH), 123.8 (CH), 124.9 (C), 124.9 (C), 125.0 (CH), 128.2 (2 × CH), 128.3 (CH),

128.6 (2 × CH), 133.4 (C), 134.3 (CH), 135.2 (CH), 136.2 (C), 150.6 (C), 151.6 (C), 155.7 (C), 171.4 (C); m/z (ESI) 490.0931 (MNa⁺. C₂₄H₂₁NNaO₇S requires 490.0931).

(2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoic acid

To a stirred solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoate (10) (45.0 mg, 0.0963 mmol) in methanol (2 mL), 1,4-dioxane (1 mL) and water (1 mL) was added cesium carbonate (40.7 mg, 0.125 mmol). The resulting reaction mixture was left to stir at room temperature for 20 h. The reaction mixture was concentrated *in vacuo*, diluted with water (10 mL) and acidified to pH 1 with 1 M aqueous hydrochloric acid. The aqueous layer was extracted with dichloromethane (3 × 20 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure to give (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoic acid as a white solid (37.0 mg, 85%). Mp 231–234 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3013 (CH), 2672 (OH), 1698 (CO), 1469 (C=C), 1273, 1150, 1062, 750; $[\alpha]_D^{24}$ +13.8 (c 0.1, MeOH); δ_H (500 MHz, CD₃OD) 3.05 (1H, dd, J 14.0, 9.6 Hz, 3-HH), 3.34 (1H, dd, J 14.0, 4.4 Hz, 3-HH), 4.48 (1H, dd, J 9.6, 4.4 Hz, 2-H), 4.97 (1H, d, J 12.5 Hz, PhCHH), 5.02 (1H, d, J 12.5 Hz, PhCHH), 7.13–7.29 (5H, m, Ph), 7.34 (1H, d, J 8.5 Hz, 4'-H), 7.43–7.48 (2H, m, 6'-H and 8'-H), 7.59 (1H, dd, J 8.5, 1.9 Hz, 3'-H), 7.72 (1H, t, J 7.8 Hz, 7'-H), 7.89 (1H, d, J 1.9 Hz, 1'-H), 8.00 (1H, d, J 8.1 Hz, 9'-H); δ_C (126 MHz, CD₃OD) 37.8 (CH₂), 56.5 (CH), 67.6 (CH₂), 120.1 (CH), 120.2 (CH), 124.1 (CH), 124.4 (CH), 125.9 (C), 126.2 (CH), 126.3 (C), 128.7 (2 × CH), 128.8 (CH), 129.4 (2 × CH), 135.7 (CH), 136.5 (C), 136.7 (CH), 138.1 (C), 151.8 (C), 153.0 (C), 158.4 (C) 174.6 (C); m/z (ESI) 476.0776 (MNa⁺. C₂₃H₁₉NNaO₇S requires 476.0774).

(2S)-2-Amino-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoic acid hydrochloride (11)

A solution of (2S)-2-[(benzyloxycarbonyl)amino]-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoic acid (25 mg, 0.055 mmol) in 6 M aqueous hydrochloric acid (2.5 mL) and 1,4-dioxane (0.5 mL) was heated under reflux for 4 h. After cooling to room temperature, the reaction mixture was concentrated *in vacuo* and the resulting residue recrystallised from methanol and diethyl ether to afford (2S)-2-amino-3-(phenoxathiin-10',10'-dioxide-2'-yl)propanoic acid hydrochloride (11) as a white solid (18 mg, 92%). Mp 235–236 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3075 (NH), 2948 (CH), 2831 (OH), 1732 (CO), 1592 (C=C), 1471, 1272, 1199, 1148, 758; $[\alpha]_D^{24}$ +30.3 (c 0.1, MeOH); δ_H (500 MHz, CD₃OD) 3.34 (1H, dd, J 14.7, 7.4 Hz, 3-HH), 3.45 (1H, dd, J 14.7, 5.9 Hz, 3-HH), 4.37 (1H, dd, J 7.4, 5.9 Hz, 2-H), 7.49–7.55 (3H, m, 4'-H, 6'-H and 8'-H), 7.72 (1H, dd, J 8.6, 1.5 Hz, 3'-H), 7.78 (1H, t, J 7.9 Hz, 7'-H), 7.99 (1H, d, J 1.5 Hz, 1'-H), 8.03 (1H, d, J 7.9 Hz, 9'-H); δ_C (126 MHz, CD₃OD) 36.4 (CH₂), 54.7 (CH), 120.2 (CH), 120.9 (CH), 124.1 (CH), 125.0 (CH), 126.3 (C), 126.4 (CH), 126.5 (C) 133.4 (C), 135.9 (CH), 136.9 (CH), 152.6 (C), 152.9 (C), 170.9 (C); m/z (ESI) 342.0405 (MNa⁺. C₁₅H₁₃NNaO₅S requires 342.0407).



2-(2'-Bromophenylthio)-17- β -estradiol-17-acetate (13)

The reaction was performed as described in general procedure A using 17- β -estradiol-17-acetate (12) (91.5 mg, 0.291 mmol). The reaction mixture was stirred at 40 °C for 4 h. Purification by flash column chromatography (hexane/dichloromethane, 3 : 2) gave 2-(2'-bromophenylthio)-17- β -estradiol-17-acetate (13) (107 mg, 73%) as a white solid. Mp 172–175 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 3406 (OH), 2924 (CH), 1724 (CO), 1481 (C=C), 1427, 1346, 1015, 891, 745; $[\alpha]_{\text{D}}^{20} +48.7$ (*c* 0.1, CHCl₃); δ_{H} (400 MHz, CDCl₃) 0.84 (3H, s, 13-CH₃), 1.21–1.61 (7H, m, 7-H₂, 8-H, 11-HH, 15-H₂ and 16-HH), 1.70–1.81 (1H, m, 9-H), 1.84–1.94 (2H, m, 11-HH and 14-H), 2.05 (3H, s, COCH₃), 2.16–2.28 (3H, m, 12-H₂ and 16-HH), 2.86–2.92 (2H, m, 6-H₂), 4.68 (1H, dd, *J* 9.0, 8.0 Hz, 17-H), 6.13 (1H, s, OH), 6.59 (1H, dd, *J* 7.8, 1.5 Hz, 6'-H), 6.82 (1H, s, 4-H), 6.99 (1H, td, *J* 7.8, 1.5 Hz, 4'-H), 7.11 (1H, td, *J* 7.8, 1.3 Hz, 5'-H), 7.41 (1H, s, 1-H), 7.52 (1H, dd, *J* 7.8, 1.3 Hz, 3'-H); δ_{C} (101 MHz, CDCl₃) 12.2 (CH₃), 21.3 (CH₃), 23.4 (CH₂), 26.3 (CH₂), 27.1 (CH₂), 27.7 (CH₂), 29.8 (CH₂), 36.9 (CH₂), 38.4 (CH), 43.0 (C), 43.8 (CH), 49.9 (CH), 82.8 (CH), 112.0 (C), 115.7 (CH), 120.8 (C), 126.6 (CH), 126.8 (CH), 128.1 (CH), 133.0 (CH), 134.2 (CH), 134.3 (C), 138.0 (C), 142.6 (C), 155.3 (C), 171.4 (C); *m/z* (ESI) 501.1091 (MH⁺). C₂₆H₃₀⁷⁹BrO₃S requires 501.1090.

(15*S*,18*S*,19*S*,22*S*,23*R*)-18-Methyl-4-oxa-11-thiahexacyclo[12.11.0.0^{3,12}.0^{5,10}.0^{15,23}.0^{18,22}]pentacosa-1(14),2,5(10),6,8,12-hexaen-19-yl acetate (14)

The reaction was performed as described in general procedure B using 2-(2'-bromophenylthio)-17- β -estradiol-17-acetate (13) (50 mg, 0.17 mmol). Purification by flash column chromatography (hexane/dichloromethane 7 : 3) gave (15*S*,18*S*,19*S*,22*S*,23*R*)-18-methyl-4-oxa-11-thiahexacyclo[12.11.0.0^{3,12}.0^{5,10}.0^{15,23}.0^{18,22}]pentacosa-1(14),2,5(10),6,8,12-hexaen-19-yl acetate (14) (32 mg, 76%) as a white solid. Mp 185–187 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat) 2928 (CH), 1724 (C=O), 1462 (C=C), 1288, 1037, 879, 752; $[\alpha]_{\text{D}}^{21} +44.9$ (*c* 0.1, CHCl₃); δ_{H} (400 MHz, CDCl₃) 0.82 (3H, s, 18-CH₃), 1.21–1.56 (7H, m, 16-HH, 20-HH, 21-H₂, 23-H and 24-H₂), 1.69–1.77 (1H, m, 15-H), 1.82–1.91 (2H, m, 16-HH and 22-H), 2.06 (3H, s, COCH₃), 2.09–2.28 (3H, m, 17-H₂ and 20-HH), 2.76–2.82 (2H, m, 25-H₂), 4.68 (1H, dd, *J* 9.1, 7.9 Hz, 19-H), 6.73 (1H, s, 2-H), 6.87–7.00 (3H, m, 6-H, 8-H and 13-H), 7.05–7.13 (2H, m, 7-H and 9-H); δ_{C} (101 MHz, CDCl₃) 12.2 (CH₃), 21.3 (CH₃), 23.4 (CH₂), 26.3 (CH₂), 27.1 (CH₂), 27.7 (CH₂), 29.3 (CH₂), 36.9 (CH₂), 38.4 (CH), 43.0 (C), 43.9 (CH), 49.9 (CH), 82.8 (CH), 116.6 (C), 117.7 (CH), 117.8 (CH), 120.6 (C), 123.7 (CH), 124.4 (CH), 126.9 (CH), 127.6 (CH), 136.8 (C), 136.9 (C), 150.0 (C), 152.4 (C), 171.3 (C); *m/z* (ESI) 443.1651 (MNa⁺). C₂₆H₂₈NaO₃S requires 443.1651.

(15*S*,18*S*,19*S*,22*S*,23*R*)-18-Methyl-4-oxa-11-thiahexacyclo[12.11.0.0^{3,12}.0^{5,10}.0^{15,23}.0^{18,22}]pentacosa-1(14),2,5(10),6,8,12-hexaen-19-ol (15)

A solution of (15*S*,18*S*,19*S*,22*S*,23*R*)-18-methyl-4-oxa-11-thiahexacyclo[12.11.0.0^{3,12}.0^{5,10}.0^{15,23}.0^{18,22}]pentacosa-1(14),2,5(10),6,8,12-hexaen-19-yl acetate (14) (17 mg, 40 μmol) in tetrahydrofuran

(0.5 mL) and methanol (0.5 mL) was treated with potassium carbonate (7.0 mg, 49 μmol). The resulting reaction mixture was left to stir at room temperature for 18 h. The reaction mixture was concentrated *in vacuo* and the residue was partitioned between a saturated aqueous solution of ammonium chloride (10 mL) and ethyl acetate (10 mL). The aqueous layer was extracted with ethyl acetate (2 \times 10 mL) and the combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. Purification by flash column chromatography (hexane/ethyl acetate 7 : 3) gave (15*S*,18*S*,19*S*,22*S*,23*R*)-18-methyl-4-oxa-11-thiahexacyclo[12.11.0.0^{3,12}.0^{5,10}.0^{15,23}.0^{18,22}]pentacosa-1(14),2,5(10),6,8,12-hexaen-19-ol (15) (14 mg, 93%) as a white solid. Mp 197–199 °C; $\nu_{\max}/\text{cm}^{-1}$ (neat), 3565 (OH), 2905 (CH), 1466 (C=C), 1443, 1215, 1065, 860, 745; $[\alpha]_{\text{D}}^{21} +89.1$ (*c* 0.1, CHCl₃); δ_{H} (400 MHz, CDCl₃) 0.77 (3H, s, 18-CH₃), 1.10–1.55 (8H, m, OH, 16-HH, 20-HH, 21-H₂, 23-H and 24-H₂), 1.65 (1H, m, 15-H), 1.83–1.90 (1H, m, 16-HH), 1.92–1.97 (1H, m, 22-H), 2.06–2.17 (2H, m, 17-H₂), 2.22–2.29 (1H, m, 20-HH), 2.76–2.82 (2H, m, 25-H₂), 3.72 (1H, t, *J* 8.4 Hz, 19-H), 6.74 (1H, s, 2-H), 6.93–7.01 (3H, m, 6-H, 8-H and 13-H), 7.07–7.12 (2H, m, 7-H and 9-H); δ_{C} (101 MHz, CDCl₃) 11.2 (CH₃), 23.3 (CH₂), 26.4 (CH₂), 27.2 (CH₂), 29.3 (CH₂), 30.7 (CH₂), 36.7 (CH₂), 38.7 (CH), 43.3 (C), 44.0 (CH), 50.1 (CH), 82.0 (CH), 116.6 (C), 117.7 (CH), 117.8 (CH), 120.6 (C), 123.7 (CH), 124.4 (CH), 126.9 (CH), 127.6 (CH), 136.9 (C), 137.1 (C), 150.0 (C), 152.4 (C); *m/z* (ESI) 401.1532 (MNa⁺). C₂₄H₂₆NaO₂S requires 401.1546.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from The Carnegie Trust for the Universities of Scotland (Ph.D. studentship to A. C. D.) and the University of Glasgow is gratefully acknowledged.

Notes and references

- (a) N. N. Makhova, L. I. Belen'kii, G. A. Gazieva, I. L. Dalinger, L. S. Konstantinova, V. V. Kuznetsov, A. N. Kravchenko, M. M. Krayushkin, O. A. Rakitin, A. M. Starosotnikov, L. L. Fershtat, S. A. Shevelev, V. Z. Shirinian and V. N. Yarovenko, *Russ. Chem. Rev.*, 2020, **89**, 55; (b) V. Jaiswal, B. Mondal and J. Saha, *Asian J. Org. Chem.*, 2020, **9**, 1466; (c) S. Liu, G.-J. Deng and H. Huang, *Synlett*, 2020, **32**, 142.
- (a) N. Svenstrup and J. Becher, *Synthesis*, 1995, 215; (b) S. Pathania, R. K. Narang and R. K. Rawal, *Eur. J. Med. Chem.*, 2019, **180**, 486; (c) K. Laxmikeshav, P. Kumari and N. Shankaraiah, *Med. Res. Rev.*, 2022, **42**, 513.
- M. Li, X. Cai, Z. Qiao, K. Liu, W. Xie, L. Wang, N. Zheng and S.-J. Su, *Chem. Commun.*, 2019, **55**, 7215.



- 4 S. Ionescu, D. Gavrilu, O. Maior and M. Hillebrand, *J. Photochem. Photobiol., A*, 1999, **124**, 67.
- 5 R. Kikumoto, Y. Tamao, K. Ohkubo, T. Tezuka and S. Tonomura, *J. Med. Chem.*, 1980, **23**, 1293.
- 6 (a) M. Harfenist, D. M. Joseph, S. C. Spence, D. P. C. McGee, M. D. Reeves and H. L. White, *J. Med. Chem.*, 1997, **40**, 2466; (b) M. Harfenist, D. P. C. McGee, M. D. Reeves and H. L. White, *J. Med. Chem.*, 1998, **41**, 2118.
- 7 C. T. Supuran, A. Scozzafava, F. Briganti, G. Loloiu and O. Maior, *Eur. J. Med. Chem.*, 1998, **33**, 821.
- 8 (a) J. Wu, Z. Wang, X.-Y. Chen, Y. Wu, D. Wang, Q. Peng and P. Wang, *Sci. China: Chem.*, 2020, **63**, 336; (b) F. Juliá, Q. Shao, M. Duan, M. B. Plutschack, F. Berger, J. Mateos, C. Lu, X.-S. Xue, K. N. Houk and T. Ritter, *J. Am. Chem. Soc.*, 2021, **143**, 16041.
- 9 G. M. Bennett, M. S. Lesslie and E. E. Turner, *J. Chem. Soc.*, 1937, 444.
- 10 (a) K. Komeyama, K. Aihara, T. Kashihara and K. Takaki, *Chem. Lett.*, 2011, **40**, 1254; (b) P. Saravanan and P. Anbarasan, *Org. Lett.*, 2014, **16**, 848; (c) S. Yang, B. Feng and Y. Yang, *J. Org. Chem.*, 2017, **82**, 12430; (d) N. Liu, F. Chao, Y. Huang, Y. Wang, X. Meng, L. Wang and X. Liu, *Tetrahedron Lett.*, 2019, **60**, 151259.
- 11 F. Hu, X. Zhao, Y. Li, Y. Feng and C. Ma, *Synthesis*, 2013, **45**, 966.
- 12 B. Luo, Q. Cui, H. Luo, Y. Hu, P. Huang and S. Wen, *Adv. Synth. Catal.*, 2016, **358**, 2733.
- 13 K. Kanemoto, Y. Sakata, T. Hosoya and S. Yoshida, *Chem. Lett.*, 2020, **49**, 593.
- 14 (a) M. C. Henry, H. M. Senn and A. Sutherland, *J. Org. Chem.*, 2019, **84**, 346; (b) M. C. Henry and A. Sutherland, *Org. Lett.*, 2020, **22**, 2766; (c) M. C. Henry, V. M. Abbinante and A. Sutherland, *Eur. J. Org. Chem.*, 2020, 2819.
- 15 A. C. Dodds and A. Sutherland, *J. Org. Chem.*, 2021, **86**, 5922.
- 16 For other methods of phenol thioarylation, see: (a) C. D. Prasad, S. J. Balkrishna, A. Kumar, B. S. Bhakuni, K. Shrimali, S. Biswas and S. Kumar, *J. Org. Chem.*, 2013, **78**, 1434; (b) H. Tian, C. Zhu, H. Yang and H. Fu, *Chem. Commun.*, 2014, **50**, 8875; (c) S. Alazet and T. Billard, *Synlett*, 2015, **26**, 76; (d) T. Hostier, V. Ferey, G. Ricci, D. G. Pardo and J. Cossy, *Org. Lett.*, 2015, **17**, 3898.
- 17 The Gustafson group have reported Lewis base catalysed thioarylation reactions using a thiourea and a diarylsele- nide: (a) C. J. Nalbandian, E. M. Miller, S. T. Toenjes and J. L. Gustafson, *Chem. Commun.*, 2017, **53**, 1494; (b) C. J. Nalbandian, Z. E. Brown, E. Alvarez and J. L. Gustafson, *Org. Lett.*, 2018, **20**, 3211.
- 18 While the copper-mediated cyclisation step would be faster using iodide rather than bromide intermediates, the iodo- benzenethiol required to generate the iodinated biaryl sulfide is not readily available and is non-trivial to syn- thesize. Cyclisation of bromide intermediates **4** does require 18 hours reaction times, but the 2-bromobenze- nethiol is inexpensive and readily available, and the cyclisa- tions with these intermediates are high yielding.
- 19 C. A. Horiuchi, A. Haga and J. Y. Satoh, *Bull. Chem. Soc. Jpn.*, 1986, **59**, 2459.
- 20 (a) D. T. Racys, C. E. Warrilow, S. L. Pimlott and A. Sutherland, *Org. Lett.*, 2015, **17**, 4782; (b) D. T. Racys, S. A. I. Sharif, S. L. Pimlott and A. Sutherland, *J. Org. Chem.*, 2016, **81**, 772.
- 21 (a) S. Antoniotti, V. Dalla and E. Duñach, *Angew. Chem., Int. Ed.*, 2010, **49**, 7860; (b) M. J. Earle, U. Hakala, B. J. McAuley, M. Nieuwenhuyzen, A. Ramani and K. R. Seddon, *Chem. Commun.*, 2004, 1368.
- 22 W.-C. Gao, T. Liu, B. Zhang, X. Li, W.-L. Wei, Q. Liu, J. Tian and H.-H. Chang, *J. Org. Chem.*, 2016, **81**, 11297.
- 23 H. A. Stevenson and S. Smiles, *J. Chem. Soc.*, 1931, 718.

